Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
出版年份 2020 全文链接
标题
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
作者
关键词
-
出版物
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-03-02
DOI
10.1007/s00259-020-04709-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
- (2018) Jonathan Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying prognostic factors for well-differentiated metastatic pancreatic neuroendocrine tumours (pNETs): A retrospective international multicenter cohort study
- (2018) Paula Jimenez-Fonseca et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
- (2017) Rodney J. Hicks et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stage IV Gastro‐Entero‐Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome
- (2017) Francesco Panzuto et al. ONCOLOGIST
- An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value
- (2017) Maeva Andriantsoa et al. PLoS One
- Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines
- (2016) Margaux Foulfoin et al. ENDOCRINE-RELATED CANCER
- The epidemiology of metastases in neuroendocrine tumors
- (2016) Matias Riihimäki et al. INTERNATIONAL JOURNAL OF CANCER
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival
- (2016) Anja Rinke et al. NEUROENDOCRINOLOGY
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- (2014) S. Ezziddin et al. JOURNAL OF NUCLEAR MEDICINE
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
- (2013) John J. Zaknun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Yttrium-labelled peptides for therapy of NET
- (2012) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
- (2009) D. Putzer et al. JOURNAL OF NUCLEAR MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started